US$ 28.69
glp 1 agonists vs sglt2 inhibitors GLP-1 Receptor Agonist Therapy With and Without in Patients With Type 2 Diabetes The Role of SGLT 2
Description
Only the inputs change

In addition to blunted monoaminergic neurotransmission, it was also shown that deficiency in neurotrophic factor effects, disturbances in neurogenesis and synaptogenesis, chronic neuroinflammatory processes, and dysregulation of the hypothalamicpituitaryadrenal (HPA) axis can largely contribute to the manifestation of depressive symptoms in patients [3,4,5]

Improved tests for a random effects meta-regression with a single covariate

Mann JFE, Rossing P, Bakris G et al

It activates the same GLP-1 pathway semaglutide uses, but it also targets glucose-dependent insulinotropic polypeptide (GIP) receptors
